Filing Details
- Accession Number:
- 0001214659-21-003327
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-22 16:42:22
- Reporting Period:
- 2021-03-19
- Accepted Time:
- 2021-03-22 16:42:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1753055 | Benjamin Hickey | C/O Mirati Therapeutics 9393 Towne Centre Drive Suite 200 San Diego CA 92121 | Evp, Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-19 | 2,369 | $114.33 | 29,181 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-19 | 588 | $175.54 | 28,593 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-03-19 | 1,350 | $176.42 | 27,243 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-03-19 | 431 | $177.71 | 26,812 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non Qualified Stock Option (right to buy) | Disposition | 2021-03-19 | 2,369 | $0.00 | 2,369 | $114.33 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,116 | 2030-01-05 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020
- This transaction was executed in multiple trades at prices ranging from $175.04 to $176.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $176.048 to $177.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $177.29 to $178.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Billionaire Hedge Funds
